Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Clin Cancer Res. 2019 Aug 1;25(21):6443–6451. doi: 10.1158/1078-0432.CCR-19-0138

Figure 1. Clinical and genomic characteristics associated with FGFR1 amplification in patients with HR+/HER2− Metastatic Breast Cancer (MBC).

Figure 1.

1A) Clinical characteristics of patients with metastatic HR+/HER2− breast cancer, harboring FGFR1 amplification (FGFR1+) versus non-amplified patient (FGFR1-). PR = Progesterone Receptor.

1B) Prevalence of tumor genomic alterations in FGFR+ vs. FGFR1− patients based on SNAPSHOT profiling.